Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M. Goldman

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
British Journal of Haematology|March 12, 2011
Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemiaThomas Ernst, Joannah Score, Michael Deininger, et al.
Blood|October 24, 2002
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activityPersis J Amrolia, Steven D Reid, Liquan Gao, et al.
British Journal of Haematology|April 7, 2009
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?David Marin, Jamshid S Khorashad, Letizia Foroni, et al.
Lancet (London, England)|August 29, 2003
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfaDavid Marin, Sarah Marktel, Richard Szydlo, et al.
Blood|February 7, 2002
Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot studySelina M Luger, Stephen G O'Brien, Janina Ratajczak, et al.
European Journal of Haematology|March 13, 2003
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myelomaEvangelos Terpos, Nora Viniou, Josu de la Fuente, et al.
American Journal of Clinical Pathology|March 13, 2002
ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic responseRobert P Hasserjian, Federica Boecklin, Sally Parker, et al.
Haematologica|February 21, 2009
Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?Sergio Querol, Ghulam J Mufti, Steven G E Marsh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2008
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysisHugues de Lavallade, Jane F Apperley, Jamshid S Khorashad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progressionJamshid S Khorashad, Hugues de Lavallade, Jane F Apperley, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
British Journal of Haematology|March 12, 2011
Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemiaThomas Ernst, Joannah Score, Michael Deininger, et al.
Blood|October 24, 2002
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activityPersis J Amrolia, Steven D Reid, Liquan Gao, et al.
British Journal of Haematology|April 7, 2009
Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?David Marin, Jamshid S Khorashad, Letizia Foroni, et al.
Lancet (London, England)|August 29, 2003
Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfaDavid Marin, Sarah Marktel, Richard Szydlo, et al.
Blood|February 7, 2002
Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow: a pilot studySelina M Luger, Stephen G O'Brien, Janina Ratajczak, et al.
European Journal of Haematology|March 13, 2003
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myelomaEvangelos Terpos, Nora Viniou, Josu de la Fuente, et al.
American Journal of Clinical Pathology|March 13, 2002
ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic responseRobert P Hasserjian, Federica Boecklin, Sally Parker, et al.
Haematologica|February 21, 2009
Cord blood stem cells for hematopoietic stem cell transplantation in the UK: how big should the bank be?Sergio Querol, Ghulam J Mufti, Steven G E Marsh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2008
Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysisHugues de Lavallade, Jane F Apperley, Jamshid S Khorashad, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progressionJamshid S Khorashad, Hugues de Lavallade, Jane F Apperley, et al.
Pageof 10